2022 Q3 Trading Statement

Another quarter of strong growth underpinned by positive volume/mix

• Q3 Reported revenue +16.1%; organic +8.1% with 5.5% price, 2.6% volume/mix
• 9m Reported revenue +14.4%; organic +10.3% with 4.0% price, 6.3% volume/mix
• E-commerce 9% of total revenue with continued growth in the high teens
• Healthy power brand Q3 organic revenue growth +7.4%; 9m +11.3%

Pricing and efficiencies offsetting inflationary pressures

• Q3 Reported operating profit +12.2% to £569m; margin 19.7% down 70bps
• Q3 Adjusted operating profit2 increased 14.9% to £725m
  • Margin 25.1% down 20bps on a reported basis; down 90bps constant currency
  • Pricing and increased efficiencies fully offset inflationary pressures
  • Decline due to guided standalone costs and adverse transactional FX

Increased financial flexibility despite adverse currency

• Net debt £10,784m; further £250m of £1.5bn term loan recently repaid

Upgrade to full year guidance

• FY22 organic revenue growth now expected at 8.0-8.5%
• FY Adjusted operating profit margin2 expected to be slightly above last year at actual exchange rates (FY21: 22.8%), given recent favourable translational FX movements3

Outlook

FY22 organic revenue growth now expected at 8.0-8.5%.

At H1 Results we guided to FY22 adjusted operating profit margin slightly down at constant currency. Operational performance remains as expected with pricing and increased efficiencies fully offsetting inflationary pressures, albeit we now would expect an increase in the adverse transactional FX impact from recent currency movements of up to 30bps.

Adjusted operating margin in FY22 is now expected to be slightly above last year at actual exchange rates (FY21: 22.8%), given recent favourable translational FX movements3.

Presentation for analysts and shareholders:

A short presentation followed by Q&A will be hosted by Tobias Hestler, Chief Financial Officer and Sonya Ghobrial, Head of Investor Relations at 9 am GMT (10 am CET) on 10 November 2022, which can be accessed at www.haleon.com/investors.

For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:

UK: 0800 640 6441

US: +1 855 9796 654

All other: +44 203 936 2999

Passcode: 724755

An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors

About Haleon plc

Haleon (LSE / HLN, NYSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon’s purpose - to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Other. Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com

For the full report please view here.

1. _{All numbers within the release are unauditedand are organic unless referenced otherwise. The commentary in this announcement contains forward looking statements and should be read in conjunction with the cautionary note on page 8}
2. _{Organic revenue growth, Adjusted operating profit, Adjusted operating profit margin are non-IFRS measures; definitions and calculations of non-IFRS measures can be found on pages 8-12}
3. _{Assuming spot rates as at 31 October 2022 are sustained}